Insider track record Other Across 31 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by David Redfern. Insider active across 1 company, notably GSK plc. Aggregated, 105 disclosures have been logged. Activity tracked since 9 August 2023. The latest transaction was filed on 9 June 2026 (Purchase). Regulator: RNS (LSE). The full history is free.
Declarations 105 total
● President, Corporate Development · Executives · 9 Jun 2026 · GSK plc 14 shares @ £18.8393 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:9614374-3 Ideal exit: 6 Mar 2027 (T+270) ● President, Corporate Development · Executives · 9 Jun 2026 · GSK plc 14 shares @ £18.8393 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:03338973-0058-4811-9fe5-7b22157346a2-3 Ideal exit: 6 Mar 2027 (T+270) ● President, Corporate Development · Executives · 12 May 2026 · GSK plc 14 shares @ £18.6557 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:eaad27f1-a91f-4bc4-815a-149202956de0-3 Ideal exit: 6 Feb 2027 (T+270) ● President, Corporate Development · Executives · 14 Apr 2026 · GSK plc 745 shares @ £21.67 0.0000% mcap 0.1% of flow GB00BN7SWP63⌘ RNS:ca89baf1-aabf-4020-b0fe-d5c65c1b3a57-5 ● President, Corporate Development · Executives · 13 Apr 2026 · GSK plc 10 shares @ £21.709 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:bae2311e-28b0-4835-a894-0209eedccba9-3 Ideal exit: 8 Jan 2027 (T+270) ● President Corporate Development · Executives · 10 Apr 2026 · GSK plc 17 shares @ £21.6965 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-0 Ideal exit: 5 Jan 2027 (T+270) ● President Corporate Development · Executives · 10 Apr 2026 · GSK plc 6 shares @ £21.6967 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-2 Ideal exit: 5 Jan 2027 (T+270) ● President Corporate Development · Executives · 9 Apr 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:66208821-3d67-43ba-837e-411f45d449f1-10 Ideal exit: 4 Jan 2027 (T+270) ● President Corporate Development · Executives · 9 Apr 2026 · GSK plc 67 shares @ £21.3387 0.0000% mcap 0.0% of flow GB00BN7SWP63⌘ RNS:5b5d692c-e307-4a46-a436-f5464b4ee34b-4 Ideal exit: 4 Jan 2027 (T+270) ● President, Corporate Development · Executives · 10 Mar 2026 · GSK plc 12 shares @ £20.7167 0.0% of flow GB00BN7SWP63⌘ RNS:08be650c-10c4-4fa5-9cae-5b89efa04716-3 Ideal exit: 5 Dec 2026 (T+270) ● President, Corporate Development · Executives · 13 Feb 2026 · GSK plc 171,300 shares 0
GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-16 ● President, Corporate Development · Executives · 13 Feb 2026 · GSK plc 80,511 shares @ £21.6002 9.2% of flow GB00BN7SWP63⌘ RNS:9e068048-67e6-4a53-8636-ebe7180e6da4-17 ● President, Corporate Development · Executives · 12 Feb 2026 · GSK plc 19,494 shares @ £21.50 2.2% of flow GB00BN7SWP63⌘ RNS:6207777f-2477-470b-868f-21f92714189a-5 ● President, Corporate Development · Executives · 12 Feb 2026 · GSK plc 143,579 shares @ £21.50 16.4% of flow GB00BN7SWP63⌘ RNS:586c5c74-54b9-425a-a37c-ba21836ecce7-9 ● President, Corporate Development · Executives · 10 Feb 2026 · GSK plc 12 shares @ £21.7917 0.0% of flow GB00BN7SWP63⌘ RNS:f7024c14-f781-4e48-a904-495085bc7ca2-3 Ideal exit: 7 Nov 2026 (T+270) ● President, Corporate Development · Executives · 9 Feb 2026 · GSK plc 34,873 shares 0
GB00BN7SWP63⌘ RNS:527591f3-f598-44b4-87bb-f5cfd91a36cb-8 ● President, Corporate Development · Executives · 9 Feb 2026 · GSK plc 16,415 shares @ £22.0998 1.9% of flow GB00BN7SWP63⌘ RNS:527591f3-f598-44b4-87bb-f5cfd91a36cb-9 ● President, Corporate Development · Executives · 5 Feb 2026 · GSK plc 100,000 shares @ £21.09 11.3% of flow GB00BN7SWP63⌘ RNS:c409022d-25c5-4968-9022-97e323559e34-0 ● President Corporate Development · Executives · 9 Jan 2026 · GSK plc 17 shares @ £18.8453 0.0% of flow GB00BN7SWP63⌘ RNS:111c1f6b-b3ce-4885-be8f-52a82b2acf50-0 Ideal exit: 6 Oct 2026 (T+270) ● President, Corporate Development · Executives · 12 Jan 2026 · GSK plc 14 shares @ £18.9321 0.0% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-45 Ideal exit: 9 Oct 2026 (T+270) ● President Corporate Development · Executives · 8 Jan 2026 · GSK plc 67 shares @ £18.9433 0.0% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-5 Ideal exit: 5 Oct 2026 (T+270) ● President Corporate Development · Executives · 8 Jan 2026 · GSK plc 0
GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-16 Ideal exit: 5 Oct 2026 (T+270) ● President, Corporate Development · Executives · 9 Jan 2026 · GSK plc 881 shares @ £18.91 0.1% of flow GB00BN7SWP63⌘ RNS:07b8fade-09b6-4441-a582-c78ac4e1b6b3-29 ● President, Corporate Development · Executives · 2 Jan 2026 · GSK plc 790 shares @ £11.39 0.0% of flow GB00BN7SWP63⌘ RNS:d1d365d8-4abe-41af-91cd-f67c2fcdf8a4-0 Ideal exit: 29 Sept 2026 (T+270) ● President, Corporate Development · Executives · 9 Dec 2025 · GSK plc 14 shares @ £18.0779 0.0% of flow GB00BN7SWP63⌘ RNS:58b71e9c-e0b4-4fdd-8b21-5f1119d38ddd-4 Ideal exit: 5 Sept 2026 (T+270) 25 of 105 declarations
Load more (80 remaining) About David Redfern Public sources indicate that David Redfern is with GSK plc, where he is currently President, Corporate Development. GSK says he joined the Executive Committee in 2008 as Chief Strategy Officer, joined GSK in 1994, and previously held senior roles covering Northern Europe, Central and Eastern Europe, and Pharma Europe. The same sources say he became chairman of ViiV Healthcare in 2011, holds a Bachelor of Science degree from Bristol University, and is a Chartered Accountant. Sources: https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/david-redfern/